Ovarian Cancer

To date, trials testing the use of immunotherapy in the treatment of ovarian cancer yielded disappointing results. However, researchers are not giving up. Instead, they’re investigating to see if immunotherapy drugs – such as PD1 and PDL-1 inhibitors – can be combined with other agents to benefit patients.

New discoveries happen often. Is there one for us?

“As the population of cancer survivors continues to grow, so does the importance of addressing the long-term sequelae of cancer treatment,” the authors wrote. “This hearing loss can result in multifaceted decrease in quality of life, and in pediatric patients it can impact social and academic development.”

Let's recognize time as the gift it is, and chart a course for making 2018 really count.

Should I be planning big, celebratory trips or my funeral? My fears may not be rational, but they're real.

Recent findings that the most common kind of ovarian cancer may start in the fallopian tubes could have implications for the prevention, diagnosis and treatment of the disease subtype.

Oliver Dorigo, M.D., Ph.D., Associate Professor of Obstetrics and Gynecology (Oncology), Stanford University Medical Center, talks about the direction of research in the ovarian cancer field going into 2018 and beyond.

No matter how cancer makes you look, you’re still you—a better you.

Oliver Dorigo, M.D., Ph.D., associate professor of Obstetrics and Gynecology (Oncology), Stanford University Medical Center, discusses the lack of effective screening methods for ovarian cancer.

Oliver Dorigo, M.D., Ph.D., Associate Professor of Obstetrics and Gynecology (Oncology), Stanford University Medical Center, discusses recent exciting developments in the ovarian cancer field.

A supplemental new drug application (sNDA) for Rubraca (rucaparib), a PARP inhibitor, has been granted a priority review by the Food and Drug Administration.

Longer time in between pre- and postoperative chemotherapy may be associated with significantly worse survival outcomes in women with ovarian cancer.